Valuation dashboard for Aytu BioPharma, Inc. (AYTU) with P/E N/A, P/B 0.58, EV/EBITDA -0.73 and dividend yield 0.00%. DCF, Graham Number and Earnings Power Value models plus sector comparison against other Healthcare companies.
Aytu BioPharma, Inc. is a specialized pharmaceutical firm dedicated to advancing and marketing innovative therapeutic drugs and consumer health products, serving both domestic U.S. and international markets.
Analysis Summary
Aytu BioPharma, Inc. reported revenue of $66.4M in the most recent fiscal year, growing at a 5-year CAGR of 19.2%.
Trailing-twelve-month margins: gross margin 62.5%, operating margin -26.8%, net margin -60.2%.
At the current price of $1.97, AYTU has negative trailing earnings (P/E not meaningful) and an ROE of -148.91%. Market capitalisation stands at $21M.
Balance sheet quality for AYTU: current ratio of 1.3. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Valuation Ratios
| Price / Book | 0.58 |
| EV / EBITDA | -0.73 |
| Dividend Yield | 0.00% |
Valuation Models
| DCF Fair Value | $-19.53 |
| vs Current Price | -1091.3% |
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| AYTU | Aytu BioPharma, Inc. | $21M | 0.58 | -148.9% | |
| TAK | Takeda Pharmaceutical Company Limited | $59.4B | 51.19 | 1.21 | 2.6% |
| TEVA | Teva Pharmaceutical Industries Limited | $45.0B | 61.47 | 5.82 | 17.8% |
| HLN | Haleon plc | $40.5B | 18.64 | 1.84 | 9.9% |
| 0M3Q.L | Zoetis Inc. | $35.4B | |||
| ZTS | Zoetis Inc. | $30.6B | 11.99 | 9.67 | 69.3% |
| HLN.L | Haleon plc | $29.4B | 18.73 | 1.85 | 9.9% |
| 0SAN.L | Sandoz Group AG | $28.3B | 52.81 | 3.84 | 7.0% |
Price
| Price | $1.97 |
| Market Cap | $21M |
| Exchange | NASDAQ |
| Country | US |
Profitability
| Return on Equity | -148.91% |
| Return on Invested Capital | -23.62% |
| Return on Assets | -30.49% |
| Gross Margin | 62.50% |
| Operating Margin | -26.79% |
| Net Margin | -60.17% |
Related companies: ADAP · ALUR · ANL · BFRI · EKSO · GOVX · NVNO
Explore sector: Healthcare · Drug Manufacturers - Specialty & Generic
More sections of AYTU: Overview · Financials · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks